These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 31518872)

  • 21. Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
    Ye YX; Zhou J; Zhou YH; Zhou Y; Song XB; Wang J; Lin L; Ying BW; Lu XJ
    Asian Pac J Cancer Prev; 2014; 15(22):9961-6. PubMed ID: 25520136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.
    Pereira WO; De Carvalho DD; Zenteno ME; Ribeiro BF; Jacysyn JF; Sardinha LR; Zanichelli MA; Hamerschlak N; Jones GE; Pagnano KB; Castro FA; Calle Y; Amarante-Mendes GP
    Cell Death Dis; 2017 Oct; 8(10):e3114. PubMed ID: 29022901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.
    Perrotti D; Harb JG
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1(Suppl 1):30-44. PubMed ID: 21299458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
    Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T
    Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of
    Deng Y; Li X; Feng J; Zhang X
    Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
    Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D
    Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
    Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
    Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
    Chen PH; Liu AJ; Ho KH; Chiu YT; Anne Lin ZH; Lee YT; Shih CM; Chen KC
    Chem Biol Interact; 2018 Aug; 291():144-151. PubMed ID: 29890129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
    Vatanmakanian M; Tavallaie M; Ghadami S
    Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein.
    Li Y; Wang H; Tao K; Xiao Q; Huang Z; Zhong L; Cao W; Wen J; Feng W
    Exp Cell Res; 2013 May; 319(8):1094-101. PubMed ID: 23428668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
    Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
    Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.
    Guo G; Kang Q; Zhu X; Chen Q; Wang X; Chen Y; Ouyang J; Zhang L; Tan H; Chen R; Huang S; Chen JL
    Oncogene; 2015 Apr; 34(14):1768-79. PubMed ID: 24837367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression.
    Bueno MJ; Pérez de Castro I; Gómez de Cedrón M; Santos J; Calin GA; Cigudosa JC; Croce CM; Fernández-Piqueras J; Malumbres M
    Cancer Cell; 2008 Jun; 13(6):496-506. PubMed ID: 18538733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.
    Huan C; Jin L; Heng W; Na A; Yuming P; Xin D; Qiaoxia Z
    Leuk Res; 2018 Dec; 75():1-6. PubMed ID: 30419548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Bamodu OA; Kuo KT; Yuan LP; Cheng WH; Lee WH; Ho YS; Chao TY; Yeh CT
    Exp Cell Res; 2018 Sep; 370(2):519-530. PubMed ID: 30017934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.